WHAT:TVT 2015 is a three-day course featuring the latest research and state-of-the-art techniques for transcatheter, aortic, and mitral valve therapies. This year’s conference will emphasize advanced imaging, bioskill demonstrations, and live case transmissions featuring the world’s leading experts. The agenda is now available online at: http://www.crf.org/tvt/the-conference/agenda.

Sessions showcasing the latest research will focus on research updates and new insights from mitral and transcatheter valve trials and registries. Among the highlights are:

MitraClip: World-wide Data and New Insights•EVEREST II 5-Year Report: Beyond the Top-Line ResultsTed E. Feldman•EVEREST REALISM: High-Risk CohortScott Lim•EVEREST REALISM: Non–High-Risk CohortSaibal Kar•New Insights From the GRASP RegistryMarco Barbanti•New Insights From the TRAMI RegistryStephan Baldus•ACCESS EU UpdateFrancesco Maisano•The European Sentinel RegistryCarlo Di Mario

The Latest Clinical Data: Follow-up Vignettes from EU TAVR Registries•ADVANCEAxel Linke•UK RegistryNeil E. Moat•FRANCE 2Helene Eltchaninoff•GARYThomas Walther

The Latest Clinical Data: Updates from the Randomized TAVR Trials and TVT•PARTNER 5-Year Follow-upE. Murat Tuzcu•CoreValve US 2-Year Follow-upMichael J. Reardon•NOTION in All-ComersLars Sondergaard•Insights From the US TVT RegistryJohn D. Carroll

The meeting will also examine new technologies for transcatheter and mitral valve therapies including:•Direct and indirect annuloplasty/ventriculoplasty devices (Carillon Device, Cardioband, Mitralign Procedure, Valcare Mitral Annuloplasty System, Guided Delivery Systems)•Transcatheter mitral valve replacement devices (Tiara, Fortis, CardiaQ, Tendyne, MValve, Cephea)•Transcatheter devices (SAPIEN XT, CoreValve Classic, LOTUS, Direct Flow, Symetis ACURATE, JenaValve, Portico, Engager, CENTERA)•Early stage TAVR systems and novel surgical valves (Venus A, Shanghai, Trinity, Valve Medical, Thubrikar, Syntheon, Sutureless Surgical Valves)•Cerebral embolic protection devices (Sentinel Dual Filter Device, Keystone Deflector Device, •New access site management systems (transfemoral and transapical)•New valvuloplasty systems and other accessories

WHY: Valvular heart disease affects a large number of people who require diagnostic procedures and long-term management. Many patients have no symptoms, but for others, if not treated, advanced heart valve disease can cause heart failure, stroke, blood clots, or death due to sudden cardiac arrest. Traditionally, valvular heart disease has been treated with surgical repair or replacement. Over the last several years, however, there have been important advances in concepts, tools, techniques, and patient selection for treatment of valvular heart disease using nonsurgical procedures. Transcatheter valve intervention offers the potential to reduce the procedural morbidity, mortality, and costs of surgical valve replacement or repair while accelerating patient recovery.

WHEN: June 4-6, 2015

WHERE:Hilton Chicago720 S. Michigan Ave.Chicago, Illinois

WHO:The course directors for TVT 2015 are:

Martin B. Leon, MDNewYork-Presbyterian Hospital/Columbia University Medical Center

Francesco Maisano, MDUniversitätsSpital Zürich

Nicolo Piazza, MD, PhDMcGill University Health Center

Mark Reisman, MDUniversity of Washington Medical Center/Regional Heart Center

Gregg W. Stone, MDNew York-Presbyterian Hospital/Columbia University Medical Center

John G. Webb, MDSt. Paul's Hospital

HOW TO REGISTER:Media may apply for registration by emailing [email protected]

For those unable to attend in person, reporters are eligible for access to Virtual TVT which provides live and on-demand viewing of the meeting sessions.

About CRFThe Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with heart disease through high quality research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. For more information, visit www.crf.org.